\
&
Contact us
\
&
Contact us
Published on | 4 months ago
ProgrammesBuilding on the revised Charter for access to research infrastructures , this new Charter will be specifically aimed at facilitating access of companies. It will make it easier for companies, especially small and medium-sized businesses (SMEs), startups and scaleups, to access Europe’s world-class research and technology infrastructures.
The Charter will help simplify access and contractual conditions of such infrastructures, ranging from advanced laboratories to large scientific instruments, pilot lines, testbeds, and more. As a result, companies will be able to test and validate their innovative solutions under the best conditions and bring them to the market more quickly.
It will also contribute to Europe’s vibrant and accessible ecosystem of research and technology infrastructures, a compelling reason for innovative companies to Choose Europe.
The Charter aims to improve access to infrastructures through six proposed principles:
Stakeholders are invited to provide their views on the design and content of the Charter by 10 December 2025. The final Charter is expected to be presented in 2026.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
